Indeed, CDK4/6 inhibition was associated with a reduction in TSC2 phosphorylation in HER2-positive breast cancer mouse models and was shown to resensitize tumors to EGFR/HER2 blockade [33]. The gene discussed is TSC2; the disease is breast cancer.